Hutner Capital Management Inc. held its stake in CVS Health Corp (NYSE:CVS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,552 shares of the pharmacy operator’s stock at the close of the 2nd quarter. Hutner Capital Management Inc.’s holdings in CVS Health were worth $447,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Jackson Grant Investment Advisers Inc. grew its stake in shares of CVS Health by 0.6% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock valued at $232,000 after buying an additional 18 shares during the period. Keel Point LLC grew its stake in shares of CVS Health by 0.7% in the 1st quarter. Keel Point LLC now owns 3,296 shares of the pharmacy operator’s stock valued at $259,000 after buying an additional 22 shares during the period. First City Capital Management Inc. grew its stake in shares of CVS Health by 0.3% in the 1st quarter. First City Capital Management Inc. now owns 12,771 shares of the pharmacy operator’s stock valued at $1,003,000 after buying an additional 40 shares during the period. Elefante Mark B grew its stake in shares of CVS Health by 0.7% in the 2nd quarter. Elefante Mark B now owns 6,400 shares of the pharmacy operator’s stock valued at $515,000 after buying an additional 45 shares during the period. Finally, Traynor Capital Management Inc. grew its stake in shares of CVS Health by 1.3% in the 2nd quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock valued at $290,000 after buying an additional 48 shares during the period. Hedge funds and other institutional investors own 82.24% of the company’s stock.

In other CVS Health news, EVP Thomas M. Moriarty sold 90,267 shares of CVS Health stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $79.61, for a total transaction of $7,186,155.87. Following the transaction, the executive vice president now owns 70,102 shares of the company’s stock, valued at approximately $5,580,820.22. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jonathan C. Roberts sold 85,743 shares of CVS Health stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $83.14, for a total transaction of $7,128,673.02. Following the transaction, the chief operating officer now directly owns 119,555 shares in the company, valued at approximately $9,939,802.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 714,125 shares of company stock worth $58,119,381. Insiders own 0.61% of the company’s stock.

CVS Health Corp (NYSE:CVS) opened at $75.12 on Monday. CVS Health Corp has a 1 year low of $66.45 and a 1 year high of $84.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. The company has a market cap of $76,095.96, a P/E ratio of 13.16, a price-to-earnings-growth ratio of 1.29 and a beta of 0.89.

CVS Health (NYSE:CVS) last posted its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm had revenue of $46.18 billion for the quarter, compared to analysts’ expectations of $46.17 billion. During the same quarter last year, the firm earned $1.64 EPS. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. sell-side analysts forecast that CVS Health Corp will post 5.9 earnings per share for the current year.

Several analysts have recently commented on the company. Royal Bank Of Canada began coverage on CVS Health in a research note on Tuesday, September 19th. They issued an “outperform” rating and a $95.00 target price for the company. Jefferies Group lifted their price target on CVS Health from $82.00 to $86.00 and gave the company a “hold” rating in a research note on Friday, September 15th. Needham & Company LLC reiterated a “hold” rating on shares of CVS Health in a research note on Sunday, September 10th. Wolfe Research downgraded CVS Health from an “outperform” rating to a “market perform” rating and cut their price target for the company from $89.00 to $82.00 in a research note on Monday, August 14th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $90.00 price target on shares of CVS Health in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $86.24.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/04/cvs-health-corp-cvs-stake-held-by-hutner-capital-management-inc.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Stock Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related stocks with our FREE daily email newsletter.